Cancer Care

Ensuring access to nutrition resources is fundamental to quality cancer care. Early and proactive nutrition care is associated with improved outcomes as patients progress through their cancer journey to cure or palliation. There is a critical need to improve the quality of life and treatment outcomes for cancer patients, particularly regarding the management of cancer cachexia and other side effects. Cancer cachexia poses a major challenge in healthcare as it leads to severe weight loss, muscle atrophy, fatigue, and inflammation, negatively impacting patients' well-being and treatment response. The lack of effective interventions and limited access to appropriate nutrition resources further compound the problem. Our research aims to address these challenges by investigating the potential of functional ingredient Oligo Fucoidan derived from marine seaweed as an adjunctive therapy for patients experiencing cachexia and management of chronic diseases that contribute to cancer risk. Through rigorous scientific research and clinical trials, we aim to demonstrate the effectiveness of Oligo Fucoidan in enhancing anti-tumor immune response, alleviating side effects of cachexia, improving quality of life, and treatment tolerance of patients. By providing a targeted nutritional or supplemental intervention, we hope to fill the existing gap in cancer care. By developing evidence-based solutions, we aim to improve patient outcomes, reduce treatment discontinuation rates, and ultimately contribute to the advancement of public health and healthcare in the field of cancer care and nutrition.

Since 2007, we have been dedicated to researching and developing brown seaweed, resulting in the identification of our Oligo Fucoidan which exhibits unique bi-directional immunomodulation effects with significant benefits in cancer management.

Milestone in the Research Journey

One significant milestone in our research journey occurred in 2017 when we successfully completed the first double-blind, randomized controlled trial at Kaohsiung Medical University. This landmark trial specifically evaluated the efficacy of Low-Molecular-Weight Fucoidan (OliFuco® Oligo Fucoidan) as a supplemental therapy in metastatic colorectal cancer patients. The trial conclusively demonstrated the effectiveness of Fucoidan in enhancing the disease control rate among these patients. The results of this trial were subsequently published in the esteemed article titled "Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial."

Additionally, combined of chemotherapeutic drug cisplatin and Hi-Q fucoidan treatment has been shown to increase the survival rate of patients with lung cancer in Taiwan (peer-reviewed research, 2018). Oligo Fucoidan also has attained its inclusion in the Dictionary of Drugs of the U.S. National Cancer Institute (NCI) (Code C170752). Additionally, we continue collaboration with esteemed research institutions, universities, and hospitals both locally in Taiwan and internationally, include the National Health Research Institutes, National Taiwan University Hospital, Taipei Medical University, Argentina's National Atomic Energy Commission, University of Buenos Aires, Shanghai Zhongshan Hospital of Fudan University, and Veterinary Cancer Center USA.